Literature DB >> 27555555

Eliminating Nox2 reactive oxygen species production protects dystrophic skeletal muscle from pathological calcium influx assessed in vivo by manganese-enhanced magnetic resonance imaging.

James A Loehr1, Gary R Stinnett1, Mayra Hernández-Rivera2, Wesley T Roten3,4, Lon J Wilson2, Robia G Pautler1, George G Rodney5.   

Abstract

KEY POINTS: Inhibiting Nox2 reactive oxygen species (ROS) production reduced in vivo calcium influx in dystrophic muscle. The lack of Nox2 ROS production protected against decreased in vivo muscle function in dystrophic mice. Manganese-enhanced magnetic resonance imaging (MEMRI) was able to detect alterations in basal calcium levels in skeletal muscle and differentiate disease status. Administration of Mn2+ did not affect muscle function or the health of the animal, and Mn2+ was cleared from skeletal muscle rapidly. We conclude that MEMRI may be a viable, non-invasive technique to monitor molecular alterations in disease progression and evaluate the effectiveness of potential therapies for Duchenne muscular dystrophy. ABSTRACT: Duchenne muscular dystrophy (DMD) is an X-linked progressive degenerative disease resulting from a mutation in the gene that encodes dystrophin, leading to decreased muscle mechanical stability and force production. Increased Nox2 reactive oxygen species (ROS) production and sarcolemmal Ca2+ influx are early indicators of disease pathology, and eliminating Nox2 ROS production reduces aberrant Ca2+ influx in young mdx mice, a model of DMD. Various imaging modalities have been used to study dystrophic muscle in vivo; however, they are based upon alterations in muscle morphology or inflammation. Manganese has been used for indirect monitoring of calcium influx across the sarcolemma and may allow detection of molecular alterations in disease progression in vivo using manganese-enhanced magnetic resonance imaging (MEMRI). Therefore, we hypothesized that eliminating Nox2 ROS production would decrease calcium influx in adult mdx mice and that MEMRI would be able to monitor and differentiate disease status in dystrophic muscle. Both in vitro and in vivo data demonstrate that eliminating Nox2 ROS protected against aberrant Ca2+ influx and improved muscle function in dystrophic muscle. MEMRI was able to differentiate between different pathological states in vivo, with no long-term effects on animal health or muscle function. We conclude that MEMRI is a viable, non-invasive technique to differentiate disease status and might provide a means to monitor and evaluate the effectiveness of potential therapies in dystrophic muscle.
© 2016 The Authors. The Journal of Physiology © 2016 The Physiological Society.

Entities:  

Keywords:  Duchenne muscular dystrophy; MEMRI; sarcolemmal calcium influx

Mesh:

Substances:

Year:  2016        PMID: 27555555      PMCID: PMC5088246          DOI: 10.1113/JP272907

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  58 in total

Review 1.  Dynamic properties of mammalian skeletal muscles.

Authors:  R I Close
Journal:  Physiol Rev       Date:  1972-01       Impact factor: 37.312

2.  Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine.

Authors:  Tahir Durmus; Rene Schilling; Patrick Doeblin; Alexander Huppertz; Bernd Hamm; Matthias Taupitz; Moritz Wagner
Journal:  Invest Radiol       Date:  2012-03       Impact factor: 6.016

3.  Involvement of stretch-activated ion channels in Ca2+ mobilization to mechanical stretch in endothelial cells.

Authors:  K Naruse; M Sokabe
Journal:  Am J Physiol       Date:  1993-04

4.  Voltage-dependent entry and generation of slow Ca2+ oscillations in glucose-stimulated pancreatic beta-cells.

Authors:  S Dryselius; E Grapengiesser; B Hellman; E Gylfe
Journal:  Am J Physiol       Date:  1999-03

5.  Increased calcium entry into dystrophin-deficient muscle fibres of MDX and ADR-MDX mice is reduced by ion channel blockers.

Authors:  O Tutdibi; H Brinkmeier; R Rüdel; K J Föhr
Journal:  J Physiol       Date:  1999-03-15       Impact factor: 5.182

6.  Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients.

Authors:  Ernesto A C Beenakker; Natalia M Maurits; Johanna M Fock; Oebele F Brouwer; Johannes H van der Hoeven
Journal:  Eur J Paediatr Neurol       Date:  2005-08-15       Impact factor: 3.140

7.  Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression.

Authors:  R J Willcocks; I A Arpan; S C Forbes; D J Lott; C R Senesac; E Senesac; J Deol; W T Triplett; C Baligand; M J Daniels; H L Sweeney; G A Walter; K Vandenborne
Journal:  Neuromuscul Disord       Date:  2014-01-11       Impact factor: 4.296

8.  Mechanosensitive ion channels in skeletal muscle from normal and dystrophic mice.

Authors:  A Franco-Obregón; J B Lansman
Journal:  J Physiol       Date:  1994-12-01       Impact factor: 5.182

Review 9.  The role of oxidative stress in skeletal muscle injury and regeneration: focus on antioxidant enzymes.

Authors:  Magdalena Kozakowska; Katarzyna Pietraszek-Gremplewicz; Alicja Jozkowicz; Jozef Dulak
Journal:  J Muscle Res Cell Motil       Date:  2016-01-04       Impact factor: 2.698

10.  In vivo axonal transport deficits in a mouse model of fronto-temporal dementia.

Authors:  Tabassum Majid; Yousuf O Ali; Deepa V Venkitaramani; Ming-Kuei Jang; Hui-Chen Lu; Robia G Pautler
Journal:  Neuroimage Clin       Date:  2014-03-31       Impact factor: 4.881

View more
  7 in total

1.  Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.

Authors:  Angus Lindsay; Alexandra Schmiechen; Christopher M Chamberlain; James M Ervasti; Dawn A Lowe
Journal:  Exp Physiol       Date:  2018-07       Impact factor: 2.969

2.  Summary of Imaging in 2020: Visualizing the Future of Healthcare with MR Imaging.

Authors:  Brooke A Corbin; Alyssa C Pollard; Matthew J Allen; Mark D Pagel
Journal:  Mol Imaging Biol       Date:  2019-04       Impact factor: 3.488

3.  The Emerging Roles of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 2 in Skeletal Muscle Redox Signaling and Metabolism.

Authors:  Carlos Henríquez-Olguín; Susanna Boronat; Claudio Cabello-Verrugio; Enrique Jaimovich; Elena Hidalgo; Thomas E Jensen
Journal:  Antioxid Redox Signal       Date:  2019-11-01       Impact factor: 8.401

4.  Coenzyme Q10 supplementation acts as antioxidant on dystrophic muscle cells.

Authors:  Daniela Sayuri Mizobuti; Aline Reis Fogaça; Fernanda Dos Santos Rapucci Moraes; Luis Henrique Rapucci Moraes; Rafael Dias Mâncio; Túlio de Almeida Hermes; Aline Barbosa Macedo; Amanda Harduim Valduga; Caroline Caramano de Lourenço; Elaine Cristina Leite Pereira; Elaine Minatel
Journal:  Cell Stress Chaperones       Date:  2019-10-16       Impact factor: 3.667

5.  Loss of peroxiredoxin-2 exacerbates eccentric contraction-induced force loss in dystrophin-deficient muscle.

Authors:  John T Olthoff; Angus Lindsay; Reem Abo-Zahrah; Kristen A Baltgalvis; Xiaobai Patrinostro; Joseph J Belanto; Dae-Yeul Yu; Benjamin J Perrin; Daniel J Garry; George G Rodney; Dawn A Lowe; James M Ervasti
Journal:  Nat Commun       Date:  2018-11-30       Impact factor: 14.919

6.  Mechanical factors tune the sensitivity of mdx muscle to eccentric strength loss and its protection by antioxidant and calcium modulators.

Authors:  Angus Lindsay; Cory W Baumann; Robyn T Rebbeck; Samantha L Yuen; William M Southern; James S Hodges; Razvan L Cornea; David D Thomas; James M Ervasti; Dawn A Lowe
Journal:  Skelet Muscle       Date:  2020-02-01       Impact factor: 4.912

7.  Molecular changes in transcription and metabolic pathways underlying muscle atrophy in the CuZnSOD null mouse model of sarcopenia.

Authors:  Kavithalakshmi Sataranatarajan; Gavin Pharaoh; Jacob L Brown; Rojina Ranjit; Katarzyna M Piekarz; Kaitlyn Street; Jonathan D Wren; Constantin Georgescu; Caroline Kinter; Michael Kinter; Willard M Freeman; Arlan Richardson; Holly Van Remmen
Journal:  Geroscience       Date:  2020-05-12       Impact factor: 7.581

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.